+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: 293T cells, Primary antibody: P08004(ATG9A Antibody) at dilution 1/240, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P08004(ATG9A Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08004(ATG9A Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

ATG9A is a critical transmembrane protein involved in autophagy, a cellular degradation pathway essential for maintaining homeostasis. As one of the few autophagy-related (ATG) proteins with a transmembrane domain, ATG9A plays a pivotal role in forming and mobilizing autophagosomal membranes. It shuttles between the trans-Golgi network, endosomes, and autophagosomes, facilitating lipid transfer and membrane expansion during autophagosome biogenesis. Dysregulation of ATG9A has been linked to neurodegenerative diseases, cancer, and metabolic disorders, highlighting its biological significance.

ATG9A antibodies are indispensable tools for studying autophagy mechanisms. They enable the detection and localization of endogenous ATG9A via techniques like Western blotting (WB), immunofluorescence (IF), and immunoprecipitation (IP). These antibodies often target specific epitopes, such as the N-terminal or C-terminal regions, to assess protein expression, post-translational modifications, or interactions with other autophagy regulators. Commercial ATG9A antibodies are typically validated in knockout cell lines to ensure specificity, as cross-reactivity with homologous proteins (e.g., ATG9B) can occur.

Research using ATG9A antibodies has advanced our understanding of its role in physiological processes like nutrient sensing, organelle quality control, and pathogen clearance. Additionally, these reagents aid in exploring therapeutic strategies targeting autophagy in diseases such as Alzheimer’s and Parkinson’s. However, variability in antibody performance across experimental conditions necessitates careful optimization and validation in each study.